Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Herbert I. Hurwitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3242-9197; OpenAlex author ID A5046311492. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper

Papers 8

  1. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Co-author DOI 10.1097/fpc.0000000000000375↗
  2. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Co-author DOI 10.1002/ijc.31171↗
  3. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Last author DOI 10.1007/s00280-017-3494-3↗
  4. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  5. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗
  6. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Last author DOI 10.1158/1078-0432.ccr-13-0926↗
  7. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? Co-author DOI 10.1002/jso.23044↗
  8. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Co-author DOI 10.1158/1078-0432.ccr-11-1387↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kouros Owzar · 3 shared papers, 2012–2019 · strength 0.17
  2. Hedy Lee Kindler · 3 shared papers, 2012–2019 · strength 0.14
  3. Andrew B. Nixon · 2 shared papers, 2013–2019 · strength 0.11
  4. Johanna C. Bendell · 2 shared papers, 2015–2018 · strength 0.11
  5. Federico Innocenti · 2 shared papers, 2012–2019 · strength 0.10
  6. Mark J. Ratain Md · 2 shared papers, 2012–2019 · strength 0.10
  7. Chen Jiang · 2 shared papers, 2012–2019 · strength 0.10
  8. Peter James O'Dwyer · 1 shared paper, 2018 · strength 0.09
  9. Emily W. Chan · 1 shared paper, 2018 · strength 0.09
  10. Nashat Y. Gabrail · 1 shared paper, 2018 · strength 0.09
  11. Elena Gabriela Chiorean · 1 shared paper, 2018 · strength 0.09
  12. James L. Abbruzzese · 1 shared paper, 2018 · strength 0.07
  13. Bensong Duan · 1 shared paper, 2018 · strength 0.07
  14. Qingyi Wei Wei · 1 shared paper, 2018 · strength 0.07
  15. Hengjun Gao · 1 shared paper, 2018 · strength 0.07
  16. Hongyu Li · 1 shared paper, 2018 · strength 0.07
  17. Fitzroy Dawkins · 1 shared paper, 2018 · strength 0.07
  18. Ashwin Reddy Sama · 1 shared paper, 2018 · strength 0.07
  19. Eileen Mary O'Reilly · 1 shared paper, 2018 · strength 0.07
  20. Chris Verslype · 1 shared paper, 2018 · strength 0.07
  21. Manuel M. Hidalgo · 1 shared paper, 2018 · strength 0.07
  22. Chung‐Pin Li · 1 shared paper, 2018 · strength 0.07
  23. Edward W. Greeno · 1 shared paper, 2018 · strength 0.07
  24. Vaibhav Sahai · 1 shared paper, 2018 · strength 0.07
  25. Kenneth H. Yu · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.